Our research is focused on mechanisms that govern the structure, function and evolution of the human antibody repertoire, and on the molecular engineering of antibodies and cytokines for basic and translational research applications.
Studies in the Christ laboratory have identified mechanisms that control the stability of human antibody therapeutics, blockbuster agents, which are among the fastest growing class of drugs in the pharmaceutical sector. The laboratory is part of the Immunology division and has extensive collaborative programs, which have highlighted the role of cytokines and membrane receptors in the development of protective immunity.
Engineered human antibodies and cytokines represent robust building blocks for the development of next generation reagents for co-crystallization, imaging and therapeutic applications. They can be generated by genetic engineering technology, completely bypassing the use of animals. We are applying our technology to structural targets, and to therapeutic targets in cancer and inflammatory diseases.
We are always looking for talented, ambitious students and postdocs to join our lab. Please contact us for further information.
In the News
2016 recipients of the Heliflite Young Explorer and CHAMP Young Pioneer Awards and the Palmer Innovation Prize announced - May 05, 2016
Antibodies on the agenda: major funding boost for Garvan immunologists - Mar 18, 2016
No more money and time down the drain say antibody experts in Nature - Feb 05, 2015
Start up company to commercialise antibody-stabilisation technology - Jan 15, 2015
Daniel Christ recognised with NHMRC Excellence Award - Nov 28, 2013
Garvan performs well in NHMRC grants round - Oct 24, 2012
Making biologically active yet stable antibodies - Jun 28, 2012
Romain Rouet wins 2011 Castle Harlan Award - Nov 09, 2011